Mylan Could Get Out Of EpiPen Price Backlash With A Little Contrition, Analyst Says
Mylan CEO Heather Bresch may have done her company little favors by arguing it couldn't reduce EpiPen's price, with one analyst telling the firm it needs to get a little contrition and acknowledge its decision to raise the medicine's cost.
You may also be interested in...
It's uncertain whether Democratic presidential candidate Hillary Clinton's attempt at drug pricing reform would be viable, but it's one analysts say to take seriously because the first step could lead to more.
Mylan's plan to provide a generic version of its emergency allergic reaction drug EpiPen may be a good PR move, but it may alienate payers further. It also has spurred new skepticism about the company's pricing practices.
There is no question that the concerns over Mylan’s price increases for EpiPen would deflate as rapidly as the price once an interchangeable generic is approved by FDA, but putting pressure on FDA to get a generic to market may be counterproductive.